- Details
- Andrea Miyahira engages with Jelani Zarif regarding his team’s paper elucidating the metabolic reprogramming of tumor-associated macrophages utilizing the potent glutamine antagonist JHU083. Their dialogue explores the intricate mechanisms underpinning glutamine metabolism within tumor cells and macrophages, unveiling the transformative impact of JHU083 on macrophage functionality. Dr. Zarif artic...
|
- Details
- Andrea Miyahira discusses a study on noninvasive detection of neuroendocrine prostate cancer with Himisha Beltran and Francesca Demichelis. Their collaborative paper, published in Cancer Discovery, introduces a targeted cell-free DNA methylation panel called NEMO (Neuroendocrine Monitoring). This panel aims to distinguish neuroendocrine prostate cancer from adenocarcinoma using DNA methylation pat...
|
- Details
- Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate AI test, highlighting its use in identifying biochemical recurrence after prostatectomy. This AI model, validated with data from key trials, not only distinguishes patients based on the aggressiveness of their disease but...
|
- Details
- Alicia Morgans engages with Noel Clarke on the critical issue of bone health in prostate cancer patients, particularly those undergoing androgen deprivation therapy (ADT). Professor Clarke shares findings from the STAMPEDE trial and other studies that highlight the high fracture rates in these patients. He criticizes the reliability of the FRAX scoring system, which was originally developed for a...
|
- Details
- Alicia Morgans interviews Thomas Zilli about the PEACE V study. The study, termed the STORM trial, investigates treatment strategies for patients with oligorecurrent prostate cancer, comparing focalized SBRT, comprehensive irradiation, and salvage lymph node dissection combined with six months of ADT. Aimed at determining the best approach for these patients, the trial specifically looks at metast...
|
- Details
- Alicia Morgans speaks with Bertrand Tombal about his presentation at EAU 2024, focusing on the European subset of the ARASENS trial. Professor Tombal discusses the importance of the data from this trial, which assessed the efficacy of adding darolutamide to standard treatment for metastatic hormone-naive prostate cancer. The trial confirmed that this combination significantly reduced mortality ris...
|
- Details
- Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed conversation, Dr. Shore explains the trial’s structure, which tested the efficacy of enzalutamide combined with leuprolide acetate or as monotherapy. Trial findings reveal a significant improvement in metastasis-free surviva...
|
- Details
- Although there has been a single retrospective study published of salvage SBRT after brachytherapy, re-irradiation post-brachytherapy (PMID: 36739178) is largely unstudied. Here we present the first prospective trial for salvage SBRT paradigm after brachytherapy, NCT03253744. Biographies: Krishnan R. Patel, MD, Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, MD Related Content...
|
- Details
- Men with localized or locally advanced prostate cancer (LPC/LAPC) are at risk of progression after radiotherapy (RT) or radical prostatectomy (RP). Using real-world data, we evaluated patient characteristics, treatment patterns, and outcomes in LPC/LAPC. Biographies: Stephen J. Freedland, MD, Urologist, Cedars-Sinari, Los Angeles, CA, Staff Physician, Durham VA Medical Center, Durham, NC. Related...
|
- Details
- Zach Klaassen and Kelvin Moses discuss the continuum of care for metastatic hormone-sensitive prostate cancer, focusing on triplet therapy. Dr. Moses highlights the ideal patient profile for this treatment, emphasizing collaboration between urology and medical oncology. They stress the manageable nature of chemotherapy and its finite duration. The conversation extends to disparities in prostate ca...
|
